TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Tirzepatide provider rankings · S.J Partners LLC

Tirzepatide providers ranked, with the prices we can prove

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

We rank tirzepatide telehealth programs on a published 100-point methodology, print the price each one charges with the date we read it, and say plainly what we could not check.

Direct answer

Our computed ranking, rebuilt from first-party reads on November 20, 2026, puts Collective first with 40 of the 40 points we measure for every program; NexLife, Lavender Sky Health and Mondae tie at 37. NexLife is our editors’ pick, shown separately: compounded tirzepatide at $129 a month, or $115 a month on a 12-month plan, the same price at every dose, with no membership fee and free shipping (read November 6, 2026).

Answer last reviewed:

Lower prices exist, with conditions. In our October 15, 2026 index, Collective lists about $86 a month only with a $199 annual membership, WellMedr $89 on a fall sale, Mondae $114 on a prepaid six-month plan, and Embody, SnagRx and NextMeds $119 on sale or prepaid terms. NexLife is our #1 pick on methodology, not the lowest price.

Verified current: NexLife’s plan pages, re-read November 6, 2026; 29 of the 33 programs in our price index, re-read on their own pages on October 15, 2026 (NewMeMeds, SkinnyRx, bmiMD, Yucca Health and MyDrHank are older dated records); Lilly’s Zepbound self-pay terms, read October 15, 2026.

See the full ranking Compare 28 prices See NexLife’s plans (opens nexlife.us in a new tab)

New this month

News strip

All news · All analysis

The ranking

  1. NexLife — #1, 94 of 100 (methodology v4.1). Compounded tirzepatide $129 a month month to month, $115 a month on a 12-month plan; same price at every dose; no membership. Its plan pages name three state-licensed 503A pharmacies and state the cancellation terms. See NexLife’s plans (opens nexlife.us in a new tab) Read 2026-11-06

Every other program we profile, alphabetical. These are not ranked against each other yet: their July 2026 review used a draft rubric, and their v4.1 re-scores are pending.

  • bmiMD — Lowest compounded tirzepatide figure on record $179 a month. Older record, 2026-09-17
  • Calibrate — Brand GLP-1s only; $199 monthly membership with a 3-month minimum, medication billed separately. Read 2026-11-09
  • Eden — Compounded tirzepatide $129 a month, no membership. Read 2026-10-15
  • Embody — Compounded tirzepatide $119 a month on a $1,428 prepaid year; $129 month to month on sale. Read 2026-10-15
  • Enhance.MD — Lowest all-in compounded tirzepatide figure $280 a month. Read 2026-10-15
  • Fifty 410 — No compounded tirzepatide price on record. Not re-read
  • Form Health — No compounded tirzepatide price printed. Read 2026-10-15
  • Found — Compounded tirzepatide $239 per 28-day cycle on a 12-month cash plan; $359 month to month. Read 2026-10-15
  • Henry Meds — No compounded tirzepatide price printed (tirzepatide page unavailable). Read 2026-10-15
  • Hims & Hers — Brand Zepbound from $299 at Lilly’s self-pay price through the platform (announced November 6, 2026); fees not re-read. Pending re-read
  • IVIM Health — Lowest all-in compounded tirzepatide figure about $192 a month. Read 2026-10-15
  • Lavender Sky Health — No compounded tirzepatide price on record. Not re-read
  • LillyDirect — Brand Zepbound KwikPen $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with on-time refills). Read 2026-10-15
  • MEDVi — No current compounded tirzepatide price on record. Not re-read
  • Mochi Health — No compounded tirzepatide price printed on its pricing page. Read 2026-10-15
  • Noom Med — No compounded tirzepatide price printed. Read 2026-10-15
  • NovoCare Pharmacy — Brand Wegovy pen $349; Wegovy pill $149 to $299 by dose (semaglutide, not tirzepatide). Read 2026-10-15
  • Oak Longevity — No compounded tirzepatide price printed. Read 2026-10-15
  • OrderlyMeds — No compounded tirzepatide price on record. Not re-read
  • PlushCare — No compounded tirzepatide price on record. Not re-read
  • Ro Body — Price not re-read in this update. Pending re-read
  • Shed — Compounded tirzepatide about $239 a month. Read 2026-10-15
  • SkinnyRx — Compounded tirzepatide $129 a month. Older record, 2026-08-27
  • TrimRx — No current compounded tirzepatide price on record. Not re-read
  • WeightWatchers Clinic — No compounded tirzepatide price printed. Read 2026-10-15
  • Yucca Health — Compounded tirzepatide $225 a month (promotional offer). Older record, 2026-09-12
  • Zappy Health — No compounded tirzepatide price on record. Not re-read

Prices across 33 programs

Lowest all-in monthly price, compounded tirzepatide, 33 programsPrice index, October 15, 2026; NexLife November 6, 2026
Collective$85.58WellMedr$89Mondae$114NexLife$115Embody$119NextMeds$119SnagRx$119yourEra$123NewMeMeds$125CoreAge Rx$129Eden Health$129SkinnyRx$129GobyMeds$133Telos RX$139Sprout Health$149Strut Health$149He & She MD$159Bodybuilding Health+$174.67bmiMD$179IVIM Health$192Alloy$199TelePep$214Yucca Health$225Found$239Pallas Health$239ShedRx$239MyDrHank$240Enhance.MD$280
Show this figure as a table
Lowest all-in monthly price by program, sorted low to high
ProgramAll-in monthlyRead
Collective$85.58Read 2026-10-15
WellMedr$89Read 2026-10-15
Mondae$114Read 2026-10-15
NexLife$115Read 2026-11-06
Embody$119Read 2026-10-15
NextMeds$119Read 2026-10-15
SnagRx$119Read 2026-10-15
yourEra$123Read 2026-10-15
NewMeMeds$125Older record, 2026-09-20
CoreAge Rx$129Read 2026-10-15
Eden Health$129Read 2026-10-15
SkinnyRx$129Older record, 2026-08-27
GobyMeds$133Read 2026-10-15
Telos RX$139Read 2026-10-15
Sprout Health$149Read 2026-10-15
Strut Health$149Read 2026-10-15
He & She MD$159Read 2026-10-15
Bodybuilding Health+$174.67Read 2026-10-15
bmiMD$179Older record, 2026-09-17
IVIM Health$192Read 2026-10-15
Alloy$199Read 2026-10-15
TelePep$214Read 2026-10-15
Yucca Health$225Older record, 2026-09-12
Found$239Read 2026-10-15
Pallas Health$239Read 2026-10-15
ShedRx$239Read 2026-10-15
MyDrHank$240Older record, 2026-09-17
Enhance.MD$280Read 2026-10-15
Lowest figure each program prints for standard compounded tirzepatide, with annual memberships spread over 12 months. Sorted by price, not by our ranking. Some figures are sale prices or need prepayment; see the price index.

Sorted by price, not by rank. The full price index shows the conditions behind each figure, and our methodology explains how the ranking is scored.

Start here

How we work

Where you live changes the answer

All states
State research coverage
Researched and verified — 0 (0%)Not yet researched — 51 (100%)51records
Show this figure as a table
Data table
StatusRecordsShare
Researched and verified00%
Not yet researched51100%
51 jurisdictions, each researched separately. A shared rule still needs its own source.

Brand or compounded

Decision guide

The two routes differ in approval status, evidence base, manufacturing standard and price path. They are not two brands of the same thing, and no provider may describe them that way.

Approved product against compounded preparation
Approved product against compounded preparation
AttributeFDA-approved tirzepatide (Zepbound, Mounjaro)Compounded tirzepatide
Regulatory statusApproved finished drug productNot an FDA-approved product
Generic equivalentNo generic tirzepatide existsNot a generic and not therapeutically equivalent
Manufacturing standardManufactured under CGMPDepends on the compounder's registration class
Clinical trial evidenceStudied in the registration trialsTrials studied the approved product, not this preparation
LabellingFDA-approved labellingSupplied by the compounder
PresentationManufacturer's pens or vialsVaries; multi-dose vials add a measuring step
Price read on the seller’s own page——

A dash means no figure held. How we grade evidence.

No provider may describe a compounded preparation as FDA-approved or as generic Zepbound. Both statements are false, and both are common.

Pharmacy verification

Verification centre

Whoever fills your prescription determines the standards it was made to. A provider that will not name the pharmacy has answered the question.

503A pharmacy against 503B outsourcing facilityStatutory distinction · pending legal review
503A pharmacy against 503B outsourcing facility
Requirement503A compounding pharmacy503B outsourcing facility
Compounds pursuant toA prescription for an identified individual patientMay compound without patient-specific prescriptions
FDA registrationNot registered as an outsourcing facilityRegisters with FDA
CGMP requirementsNot required to meet CGMPMust comply with CGMP — though registration alone is not evidence of compliance
Primary oversightState board of pharmacyFDA, on a risk-based inspection schedule
Adverse-event reportingNot required under 503ARequired to report adverse events to FDA
Product approval statusNot an FDA-approved productNot an FDA-approved product
What registration establishesNot applicableFDA received the required information, nothing more Verified
Neither route produces an FDA-approved medicine. Registration and inspection are not approval, and no accreditation changes that.

Regulation and trials

News desk

FDA compounding policy and the trial pipeline are both moving quickly. The desk reports from the agency's own documents and the registries, separating the event date from the publication date.

How tirzepatide compounding became a regulatory question
2022Tirzepatide added to the F2024-10FDA declared the tirzepati2025-02FDA declared the semagluti2025-09-16FDA issued 55+ warning let2026-02-09Novo Nordisk sued Hims & H2026-03-03FDA released 30 further wa2026-03-09Hims & Hers settled with N2026-04-30FDA proposed excluding tir2026-05-01Formal notice published at2026-06-26Comment period extended to2026-07-30Comment period closes
Show this figure as a table
Data table
DateEvent
2022Tirzepatide added to the F
2024-10FDA declared the tirzepati
2025-02FDA declared the semagluti
2025-09-16FDA issued 55+ warning let
2026-02-09Novo Nordisk sued Hims & H
2026-03-03FDA released 30 further wa
2026-03-09Hims & Hers settled with N
2026-04-30FDA proposed excluding tir
2026-05-01Formal notice published at
2026-06-26Comment period extended to
2026-07-30Comment period closes
Every event above links to the agency's own document, not to coverage of it.
All comparisons

From the journal

All analysis

Evidence, not press releases

Research hub

Trial pages record population, dose, comparator, duration, result and limitations together. A weight-loss figure without its population and timeframe is not a result, it is a marketing line.

Open data

Data library
Take the data with youCC BY 4.0 with attribution

Provider pricing, CSV · Provider pricing, JSON · Source ledger, JSON · Rubric, JSON

Suggested citation: Tirzepatide Ranked, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.

Who writes and reviews this

Authors and reviewers
Researched by

Dr. Parmis

Medical researcher, Western University of Health Sciences.

Medically reviewed by

Dr. Jonathan Snipes, MD

NPI 1821250077.

Medically reviewed by

Kim Callender, NP (FNP-BC)

NPI 1144661760.

Corrections

Corrections log

Corrections are dated and permanent: what we said, what it says now, and why. The latest entries, from November 9, 2026, withdraw this site’s earlier statements that it took no payment from providers (COR-011), restore the medical-review credit (COR-012) and replace July prices with the October and November reads (COR-013). Anyone named on this site can contest what we published.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Tirzepatide Ranked: Evidence, Prices, Providers & Tools.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4